Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6181 | 1517 | 36.4 | 74% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY | 1353914 |
29 | 3 | HIV//VIROLOGY//HIV 1 | 108954 |
773 | 2 | EFAVIRENZ//NEVIRAPINE//RALTEGRAVIR | 12242 |
6181 | 1 | ATAZANAVIR//RITONAVIR//LOPINAVIR | 1517 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ATAZANAVIR | authKW | 962215 | 7% | 45% | 106 |
2 | RITONAVIR | authKW | 905312 | 11% | 28% | 160 |
3 | LOPINAVIR | authKW | 659598 | 6% | 33% | 98 |
4 | SAQUINAVIR | authKW | 538469 | 6% | 31% | 85 |
5 | FOSAMPRENAVIR | authKW | 282085 | 2% | 48% | 29 |
6 | NELFINAVIR | authKW | 277935 | 4% | 23% | 59 |
7 | PROTEASE INHIBITORS | authKW | 276820 | 14% | 6% | 219 |
8 | AMPRENAVIR | authKW | 267258 | 2% | 40% | 33 |
9 | TIPRANAVIR | authKW | 239053 | 2% | 42% | 28 |
10 | INDINAVIR | authKW | 162757 | 3% | 16% | 50 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Infectious Diseases | 28354 | 41% | 0% | 617 |
2 | Pharmacology & Pharmacy | 15647 | 59% | 0% | 890 |
3 | Virology | 7682 | 17% | 0% | 264 |
4 | Immunology | 2913 | 22% | 0% | 336 |
5 | Microbiology | 2595 | 18% | 0% | 277 |
6 | Medical Laboratory Technology | 818 | 4% | 0% | 62 |
7 | Toxicology | 571 | 7% | 0% | 99 |
8 | Chemistry, Medicinal | 18 | 2% | 0% | 28 |
9 | Obstetrics & Gynecology | 7 | 2% | 0% | 23 |
10 | Medicine, General & Internal | 3 | 3% | 0% | 39 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PK LTD | 100635 | 0% | 100% | 5 |
2 | CLIN PHARM 533 | 90569 | 0% | 75% | 6 |
3 | ST STEPHENS | 72771 | 2% | 11% | 32 |
4 | PROGRAM HIV PREVENT TREATMENT IRD UMI 174 | 60381 | 0% | 100% | 3 |
5 | SERGAS SERV GALEGA SAUDE | 60381 | 0% | 100% | 3 |
6 | INT AIDS THER Y EVALUAT | 53670 | 0% | 67% | 4 |
7 | STAT DATA ANAL | 50362 | 2% | 10% | 24 |
8 | HIV CLIN PHARMACOL PROGRAM | 45284 | 0% | 75% | 3 |
9 | MED HIV TREATMENT UNIT | 45278 | 0% | 38% | 6 |
10 | PROGRAM HIV PREVENT TREATMENT | 42870 | 0% | 30% | 7 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTIVIRAL THERAPY | 60399 | 5% | 4% | 75 |
2 | HIV CLINICAL TRIALS | 56584 | 3% | 7% | 38 |
3 | AIDS | 31941 | 8% | 1% | 117 |
4 | HIV MEDICINE | 29440 | 3% | 4% | 40 |
5 | THERAPEUTIC DRUG MONITORING | 19334 | 4% | 2% | 60 |
6 | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 18811 | 10% | 1% | 149 |
7 | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 15987 | 4% | 1% | 58 |
8 | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 7594 | 5% | 1% | 69 |
9 | CLINICAL PHARMACOKINETICS | 7146 | 2% | 1% | 29 |
10 | CURRENT OPINION IN HIV AND AIDS | 6177 | 1% | 2% | 16 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ATAZANAVIR | 962215 | 7% | 45% | 106 | Search ATAZANAVIR | Search ATAZANAVIR |
2 | RITONAVIR | 905312 | 11% | 28% | 160 | Search RITONAVIR | Search RITONAVIR |
3 | LOPINAVIR | 659598 | 6% | 33% | 98 | Search LOPINAVIR | Search LOPINAVIR |
4 | SAQUINAVIR | 538469 | 6% | 31% | 85 | Search SAQUINAVIR | Search SAQUINAVIR |
5 | FOSAMPRENAVIR | 282085 | 2% | 48% | 29 | Search FOSAMPRENAVIR | Search FOSAMPRENAVIR |
6 | NELFINAVIR | 277935 | 4% | 23% | 59 | Search NELFINAVIR | Search NELFINAVIR |
7 | PROTEASE INHIBITORS | 276820 | 14% | 6% | 219 | Search PROTEASE+INHIBITORS | Search PROTEASE+INHIBITORS |
8 | AMPRENAVIR | 267258 | 2% | 40% | 33 | Search AMPRENAVIR | Search AMPRENAVIR |
9 | TIPRANAVIR | 239053 | 2% | 42% | 28 | Search TIPRANAVIR | Search TIPRANAVIR |
10 | INDINAVIR | 162757 | 3% | 16% | 50 | Search INDINAVIR | Search INDINAVIR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | JUSTESEN, US , (2008) PROTEASE INHIBITOR PLASMA CONCENTRATIONS IN HIV ANTIRETROVIRAL THERAPY.DANISH MEDICAL BULLETIN. VOL. 55. ISSUE 4. P. 165 -185 | 117 | 59% | 8 |
2 | PUNYAWUDHO, B , SINGKHAM, N , THAMMAJARUK, N , DALODOM, T , KERR, SJ , BURGER, DM , RUXRUNGTHAM, K , (2016) THERAPEUTIC DRUG MONITORING OF ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 12. P. 1583 -1595 | 74 | 56% | 0 |
3 | ASPIROZ, EL , BUELGA, DS , FIGUEROA, SC , GALERA, RML , PASCUET, ER , HURLE, ADG , SANCHEZ, MJG , (2011) POPULATION PHARMACOKINETICS OF LOPINAVIR/RITONAVIR (KALETRA) IN HIV-INFECTED PATIENTS.THERAPEUTIC DRUG MONITORING. VOL. 33. ISSUE 5. P. 573 -582 | 49 | 79% | 7 |
4 | WEISS, J , HAEFELI, WE , (2010) IMPACT OF ATP-BINDING CASSETTE TRANSPORTERS ON HUMAN IMMUNODEFICIENCY VIRUS THERAPY.INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 280. VOL. 280. ISSUE . P. 219-279 | 93 | 42% | 13 |
5 | LA PORTE, CJL , (2009) SAQUINAVIR, THE PIONEER ANTIRETROVIRAL PROTEASE INHIBITOR.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 5. ISSUE 10. P. 1313-1322 | 49 | 72% | 11 |
6 | MCCORMACK, SA , BEST, BM , (2014) PROTECTING THE FETUS AGAINST HIV INFECTION: A SYSTEMATIC REVIEW OF PLACENTAL TRANSFER OF ANTIRETROVIRALS.CLINICAL PHARMACOKINETICS. VOL. 53. ISSUE 11. P. 989 -1004 | 52 | 54% | 8 |
7 | BENTUE-FERRER, D , ARVIEUX, C , TRIBUT, O , RUFFAULT, A , BELLISSANT, E , (2009) CLINICAL PHARMACOLOGY, EFFICACY AND SAFETY OF ATAZANAVIR: A REVIEW.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 5. ISSUE 11. P. 1455-1468 | 50 | 65% | 17 |
8 | JANNEH, O , BRAY, PG , JONES, E , WYEN, C , CHIBA, P , BACK, DJ , KHOO, SH , (2010) CONCENTRATION-DEPENDENT EFFECTS AND INTRACELLULAR ACCUMULATION OF HIV PROTEASE INHIBITORS IN CULTURED CD4 T CELLS AND PRIMARY HUMAN LYMPHOCYTES.JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. VOL. 65. ISSUE 5. P. 906 -916 | 45 | 70% | 4 |
9 | ASPIROZ, EL , FIGUEROA, SEC , HURLE, ADG , SANCHEZ, MJG , (2013) NEW STRATEGIES IN THE OPTIMISATION OF LOPINAVIR/RITONAVIR DOSES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS.ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. VOL. 31. ISSUE 1. P. 36-43 | 46 | 60% | 1 |
10 | BUCKOREELALL, K , CRESSEY, TR , KING, JR , (2012) PHARMACOKINETIC OPTIMIZATION OF ANTIRETROVIRAL THERAPY IN PREGNANCY.CLINICAL PHARMACOKINETICS. VOL. 51. ISSUE 10. P. 639 -659 | 48 | 53% | 14 |
Classes with closest relation at Level 1 |